BLIMP BioPharma, Inc.: Developing drugs for targeted gene therapy to treat and potentially cure cancer

1

Licensed II issued PRDM gene and protein (a family of 16 genes/proteins) modulation patents & filed 7 cancer product specific provisional patents.

2

Raised seed funds and signed up officers & advisors & strategic partners. Continued contact with key pharma companies in advance of selling them our product candidates.

3

Successful study of breast cancer product published in Nanomedicine journal. Excellent proof of principle data in lung, colon and myeloma cancers.

4

Collaborations/Agreements for lab time and studies established. Selected by UC Davis Office of Research for inclusion in the DRIVE program and lab access at the UCD Life Science Innovation Center.

5

Hired 3 PhD level lab oriented scientists with cancer study experience.

6

Strong expertise at Board level and advisory level in RNA Inhibition, Drug Delivery Systems and Strategic Partnering.

7

Term sheet from High Net Worth Investors and Venture Capitalists for $1 million of $2.5 million raise target

BLIMP BioPharma, Inc.

Developing drugs for targeted gene therapy to treat and potentially cure cancer

Highlights

Our Team

Downloads